Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection

BACKGROUND: Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological e...

Descripción completa

Detalles Bibliográficos
Autores principales: Panelli, Monica C, Stashower, Mitchell E, Slade, Herbert B, Smith, Kina, Norwood, Christopher, Abati, Andrea, Fetsch, Patricia, Filie, Armando, Walters, Shelley-Ann, Astry, Calvin, Aricó, Eleonora, Zhao, Yingdong, Selleri, Silvia, Wang, Ena, Marincola, Francesco M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1839129/
https://www.ncbi.nlm.nih.gov/pubmed/17222352
http://dx.doi.org/10.1186/gb-2007-8-1-r8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1839129/
https://www.ncbi.nlm.nih.gov/pubmed/17222352
http://dx.doi.org/10.1186/gb-2007-8-1-r8

Ejemplares similares